TAM receptor signaling in immune homeostasis

Annual Review of Immunology

Volumn 33, Issue , 2015, Pages 355-391

  Rothlin, Carla V ^a   Carrera Silva, Eugenio A ^a   Bosurgi, Lidia ^a   Ghosh, Sourav ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AXL; GAS6; MERTK; PROS1; TYRO3

Indexed keywords

LIGAND; PROTEIN TYROSINE KINASE; TAM PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CLONING; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME STRUCTURE; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DISEASE PREDISPOSITION; GENETICS; IMMUNITY; METABOLISM; PHYSIOLOGY;

ANIMALS; DISEASE SUSCEPTIBILITY; HOMEOSTASIS; HUMANS; IMMUNITY; LIGANDS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84927593061     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112103     Document Type: Article

References (201)

1. Medzhitov R. 2009. Approaching the asymptote: 20 years later. Immunity 30:766-75
2. Hogquist KA, Baldwin TA, Jameson SC. 2005. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol. 5:772-82
3. Gallegos AM, Bevan MJ. 2006. Central tolerance: good but imperfect. Immunol. Rev. 209:290-96
4. Mathis D, Benoist C. 2009. Aire. Annu. Rev. Immunol. 27:287-312
5. Nemazee D. 2006. Receptor editing in lymphocyte development and central tolerance. Nat. Rev. Immunol. 6:728-40
6. Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30:531-64
7. Sharpe AH. 2009. Mechanisms of costimulation. Immunol. Rev. 229:5-11
8. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. 2011. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol. Rev. 241:180-205
9. Pentcheva-Hoang T, Corse E, Allison JP. 2009. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 229:67-87
10. Kaech SM, CuiW. 2012. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12:749-61
11. Serhan CN, Chiang N, Van Dyke TE. 2008. Resolving inflammation: dual anti-inflammatory and proresolution lipid mediators. Nat. Rev. Immunol. 8:349-61
12. EckhartW,HutchinsonMA, Hunter T. 1979. An activity phosphorylating tyrosine in polyomaTantigen immunoprecipitates. Cell 18:925-33
13. Lai C, Lemke G. 1991. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6:691-704
14. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-34
15. Crosier PS, Lewis PM, Hall LR, Vitas MR, Morris CM, et al. 1994. Isolation of a receptor tyrosine kinase (DTK) from embryonic stem cells: structure, genetic mapping and analysis of expression. Growth Factors 11:125-36
16. Fujimoto J, Yamamoto T. 1994. brt, a mouse gene encoding a novel receptor-type protein-tyrosine kinase, is preferentially expressed in the brain. Oncogene 9:693-98
17. Ohashi K, Mizuno K, Kuma K, Miyata T, Nakamura T. 1994. Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 9:699-705
18. Dai W, Pan H, Hassanain H, Gupta SL, Murphy MJ Jr. 1994. Molecular cloning of a novel receptor tyrosine kinase, tif, highly expressed in human ovary and testis. Oncogene 9:975-79
19. Mark MR, ScaddenDT, Wang Z, Gu Q, Goddard A, Godowski PJ. 1994. rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J. Biol. Chem. 269:10720-28
20. Lai C, GoreM, Lemke G. 1994. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene 9:2567-78
21. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, et al. 1991. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11:5016-31
22. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, et al. 1991. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6:2113-20
23. Rescigno J, Mansukhani A, Basilico C. 1991. A putative receptor tyrosine kinase with unique structural topology. Oncogene 6:1909-13
24. Jia R, Hanafusa H. 1994. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J. Biol. Chem. 269:1839-44
25. Jia R,Mayer BJ,Hanafusa T,HanafusaH. 1992. A novel oncogene, v-ryk, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J. Virol. 66:5975-87
26. Graham DK,DawsonTL, Mullaney DL, SnodgrassHR, Earp HS. 1994. Cloning andmRNAexpression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 5:647-57
27. Di Scipio RG, Hermodson MA, Yates SG, Davie EW. 1977. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 16:698-706
28. Stitt TN, Conn G, Gore M, Lai C, Bruno J, et al. 1995. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80:661-70
29. Dahlback B, Lundwall A, Stenflo J. 1986. Primary structure of bovine vitamin K-dependent protein S. PNAS 83:4199-203
30. Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, et al. 1986. Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. PNAS 83:6716-20
31. Manfioletti G, Brancolini C, Avanzi G, Schneider C. 1993. The protein encoded by a growth arrestspecific gene ( gas6) is a newmember of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol. Cell. Biol. 13:4976-85
32. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, et al. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type. Nature 427:537-41
33. Leventis PA, Grinstein S. 2010. The distribution and function of phosphatidylserine in cellular membranes. Annu. Rev. Biophys. 39:407-27
34. Suzuki J, Umeda M, Sims PJ, Nagata S. 2010. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468:834-38
35. Burstyn-Cohen T, Heeb MJ, Lemke G. 2009. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J. Clin. Investig. 119:2942-53
36. Saller F, Brisset AC, Tchaikovski SN, Azevedo M, Chrast R, et al. 2009. Generation and phenotypic analysis of protein S-deficient mice. Blood 114:2307-14
37. Fernandez JA, Heeb MJ, Xu X, Singh I, Zlokovic BV, Griffin JH. 2009. Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 94:1721-31
38. Heeb MJ, Rosing J, BakkerHM, Fernandez JA, Tans G, Griffin JH. 1994. Protein S binds to and inhibits factor Xa. PNAS 91:2728-32
39. Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. 1997. Requirement of γ-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem. J. 323(Pt. 2):387-92
40. Hasanbasic I, Rajotte I, BlosteinM. 2005. The role of gamma-carboxylation in the anti-apoptotic function of gas6. J. Thromb. Haemost. 3:2790-97
41. Benzakour O, Kanthou C. 2000. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 95:2008-14
42. Anderson HA,Maylock CA,Williams JA, Paweletz CP, Shu H, Shacter E. 2003. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat. Immunol. 4:87-91
43. Morboeuf O, Borgel D, Gaussem P, Vincenot A, Pittet JL, et al. 2000. Characterization of cleaved plasma protein S with a monoclonal antibody-based assay. Thromb. Haemost. 84:604-10
44. Andersson HM, Arantes MJ, Crawley JT, Luken BM, Tran S, et al. 2010. Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood 115:4878-85
45. Evenas P, Dahlback B, Garcia de Frutos P. 2000. The first laminin G-type domain in the SHBG-like region of protein S contains residues essential for activation of the receptor tyrosine kinase sky. Biol. Chem. 381:199-209
46. Evenas P, Garcia De Frutos P, Linse S,Dahlback B. 1999. Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein. Eur. J. Biochem. 266:935-42
47. Nyberg P, He X, Hardig Y, Dahlback B, Garcia de Frutos P. 1997. Stimulation of Sky tyrosine phosphorylation by bovine protein S: domains involved in the receptor-ligand interaction. Eur. J. Biochem. 246:147-54
48. Rodriguez de Cordoba S, Perez-Blas M, Ramos-Ruiz R, Sanchez-Corral P, Pardo-Manuel de Villena F, Rey-Campos J. 1994. The gene coding for the β-chain of C4b-binding protein (C4BPB) has become a pseudogene in the mouse. Genomics 21:501-9
49. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, et al. 2006. Structural basis for Gas6-Axl signalling. EMBO J. 25:80-87
50. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. 2011. Shedding of theMer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J. Biol. Chem. 286:33335-44
51. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. 1995. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J. Biol. Chem. 270:551-57
52. Costa M, Bellosta P, Basilico C. 1996. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. J. Cell Physiol. 168:737-44
53. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, et al. 2007. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109:1026-33
54. Ling L, TempletonD,KungHJ. 1996. Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase. J. Biol. Chem. 271:18355-62
55. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, et al. 2012. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined posttranslational modifications in man and mouse. Nucleic Acids Res. 40:D261-70
56. Staub E, Rosenthal A, Hinzmann B. 2004. Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome. Cell Signal. 16:435-56
57. Lu Q, Lemke G. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293:306-11
58. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, et al. 1996. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, andMer receptor tyrosine kinases. J. Biol. Chem. 271:30022-27
59. Bhattacharyya S, Zagorska A, Lew ED, Shrestha B, Rothlin CV, et al. 2013. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14:136-47
60. Blum JS,Wearsch PA, Cresswell P. 2013. Pathways of antigen processing. Annu. Rev. Immunol. 31:443-73
61. Saraiva M, O'Garra A. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10:170-81
62. Carrera Silva EA, Chan PY, Joannas L, Errasti AE, Gagliani N, et al. 2013. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 39:160-70
63. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. 2007. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131:1124-36
64. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, et al. 2006. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203:1891-901
65. Camenisch TD, Koller BH, Earp HS, Matsushima GK. 1999. A novel receptor tyrosine kinase, Mer, inhibits TNF-αproduction and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162:3498-503
66. Scutera S, FraoneT,Musso T, Cappello P, Rossi S, et al. 2009. Survival andmigration of human dendritic cells are regulated by an IFN-α-inducible Axl/Gas6 pathway. J. Immunol. 183:3004-13
67. Yoshimura A, Naka T, Kubo M. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7:454-65
68. Smiley ST, Boyer SN, Heeb MJ, Griffin JH, Grusby MJ. 1997. Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. PNAS 94:11484-89
69. Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady-Cain RL, et al. 2005. Membrane phosphatidylserine distribution as a non-apoptotic signallingmechanism in lymphocytes. Nat. Cell Biol. 7:808-16
70. Fischer K, Voelkl S, Berger J, Andreesen R, Pomorski T, Mackensen A. 2006. Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood 108:4094-101
71. Dillon SR, Constantinescu A, Schlissel MS. 2001. Annexin V binds to positively selected B cells. J. Immunol. 166:58-71
72. Hochreiter-Hufford A, Ravichandran KS. 2013. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb. Perspect. Biol. 5:a008748
73. StarkMA, Huo Y, Burcin TL,MorrisMA, OlsonTS, LeyK. 2005. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22:285-94
74. Bosurgi L, Bernink JH, Delgado Cuevas V, Gagliani N, Joannas L, et al. 2013. Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. PNAS 110:13091-96
75. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, et al. 2012. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13:1118-28
76. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, et al. 2014. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40:274-88
77. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, et al. 2001. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411:207-11
78. SeitzHM, Camenisch TD, LemkeG, Earp HS, Matsushima GK. 2007. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178:5635-42
79. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, et al. 2002. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mermembrane tyrosine kinase. J. Exp. Med. 196:135-40
80. Tibrewal N, Wu Y, D'Mello V, Akakura R, George TC, et al. 2008. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation ofmultiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J. Biol. Chem. 283:3618-27
81. Sen P, Wallet MA, Yi Z, Huang Y, Henderson M, et al. 2007. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-κB activation in dendritic cells. Blood 109:653-60
82. Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. 2013. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 341:403-6
83. Nakano T, Ishimoto Y, Kishino J, Umeda M, Inoue K, et al. 1997. Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene. J. Biol. Chem. 272:29411-14
84. Nishi C, Toda S, Segawa K, Nagata S. 2014. Tim4-and MerTK-mediated engulfment of apoptotic cells by mouse resident peritoneal macrophages. Mol. Cell. Biol. 34:1512-20
85. Finnemann SC, Nandrot EF. 2006. MerTK activation during RPE phagocytosis in vivo requires αVβ5 integrin. Adv. Exp. Med. Biol. 572:499-503
86. Nandrot E, Dufour EM, Provost AC, Pequignot MO, Bonnel S, et al. 2000. Homozygous deletion in the coding sequence of the c-mer gene in RCS rats unravels general mechanisms of physiological cell adhesion and apoptosis. Neurobiol. Dis. 7:586-99
87. D'Cruz PM, Yasumura D, Weir J, Matthes MT, Abderrahim H, et al. 2000. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum. Mol. Genet. 9:645-51
88. Feng W, Yasumura D, Matthes MT, LaVail MM, Vollrath D. 2002. Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells. J. Biol. Chem. 277:17016-22
89. Gal A, Li Y, Thompson DA, Weir J, Orth U, et al. 2000. Mutations inMERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat. Genet. 26:270-71
90. XiongW, Chen Y,Wang H,Wu H, Lu Q, Han D. 2008. Gas6 and the Tyro 3 receptor tyrosine kinase subfamily regulate the phagocytic function of Sertoli cells. Reproduction 135:77-87
91. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, et al. 1999. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398:723-28
92. ChungWS, Clarke LE, Wang GX, Stafford BK, Sher A, et al. 2013. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504:394-400
93. Rothlin CV, Lemke G. 2010. TAM receptor signaling and autoimmune disease. Curr. Opin. Immunol. 22:740-46
94. Lemke G, Burstyn-Cohen T. 2010. TAM receptors and the clearance of apoptotic cells. Ann. NY Acad. Sci. 1209:23-29
95. Furie B, Furie BC. 2008. Mechanisms of thrombus formation. N. Engl. J. Med. 359:938-49
96. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, et al. 2005. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Investig. 115:237-46
97. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, et al. 2001. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7:215-21
98. Cosemans JM, Van Kruchten R, Olieslagers S, Schurgers LJ, Verheyen FK, et al. 2010. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J. Thromb. Haemost. 8:1797-808
99. Ruan GX, Kazlauskas A. 2012. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 31:1692-703
100. Ruan GX, Kazlauskas A. 2013. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J. Biol. Chem. 288:21161-72
101. Holland SJ, Pan A, Franci C, Hu Y, Chang B, et al. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70:1544-54
102. Li Y, Ye X, Tan C, Hongo JA, Zha J, et al. 2009. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28:3442-55
103. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, et al. 2004. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J. Mol. Cell. Cardiol. 37:881-87
104. Melaragno MG, Wuthrich DA, Poppa V, Gill D, Lindner V, et al. 1998. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ. Res. 83:697-704
105. Fair DS, Marlar RA, Levin EG. 1986. Human endothelial cells synthesize protein S. Blood 67:1168-71
106. Healy AM, Schwartz JJ, ZhuX,Herrick BE, Varnum B, FarberHW. 2001. Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am. J. Physiol. Lung. Cell. Mol. Physiol. 280:L1273-81
107. Nakano T, Higashino K, Kikuchi N, Kishino J, Nomura K, et al. 1995. Vascular smooth muscle cellderived, Gla-containing growth-potentiating factor for Ca2+-mobilizing growth factors. J. Biol. Chem. 270:5702-5
108. Kim YS, Jung SH, Jung DH, Choi SJ, Lee YR, Kim JS. 2014. Gas6 stimulates angiogenesis of human retinal endothelial cells and of zebrafish embryos via ERK1/2 signaling. PLOS ONE 9:e83901
109. Mosnier LO, Zlokovic BV, Griffin JH. 2007. The cytoprotective protein C pathway. Blood 109:3161-72
110. Zhu D, Wang Y, Singh I, Bell RD, Deane R, et al. 2010. Protein S controls hypoxic/ischemic bloodbrain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood 115:4963-72
111. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. 1992. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. PNAS 89:2317-20
112. Nylander A, Hafler DA. 2012. Multiple sclerosis. J. Clin. Investig. 122:1180-88
113. HoehnHJ, Kress Y, Sohn A, Brosnan CF, Bourdon S, Shafit-Zagardo B. 2008. Axl-/- mice have delayed recovery and prolonged axonal damage following cuprizone toxicity. Brain Res. 1240:1-11
114. Binder MD, CateHS, Prieto AL, KemperD, Butzkueven H, et al. 2008. Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. J. Neurosci. 28:5195-206
115. Binder MD, Xiao J, Kemper D, Ma GZ,Murray SS, Kilpatrick TJ. 2011. Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination. PLOS ONE 6:e17727
116. Tsiperson V, Li X, Schwartz GJ, Raine CS, Shafit-Zagardo B. 2010. GAS6 enhances repair following cuprizone-induced demyelination. PLOS ONE 5:e15748
117. Weinger JG, Brosnan CF, Loudig O, Goldberg MF,Macian F, et al. 2011. Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J. Neuroinflamm. 8:49
118. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, HellenthalG, Pirinen M, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214-19
119. Ma GZ, Stankovich J, Australia and New Zealand Multiple Sclerosis Genetics Consortium, Kilpatrick TJ, BinderMD, Field J. 2011. Polymorphisms in the receptor tyrosine kinaseMERTKgene are associated with multiple sclerosis susceptibility. PLOS ONE 6:e16964
120. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, et al. 2014. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:519-23
121. Ji R, Tian S, Lu HJ, Lu Q, Zheng Y, et al. 2013. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J. Immunol. 191:6165-77
122. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, et al. 2014. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17:131-43
123. Grommes C, Lee CY, Wilkinson BL, Jiang Q, Koenigsknecht-Talboo JL, et al. 2008. Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J. Neuroimmune Pharmacol. 3:130-40
124. Shankar SL, O'Guin K, Kim M, Varnum B, Lemke G, et al. 2006. Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor α-induced apoptosis. J. Neurosci. 26:5638-48
125. Baumann I,Kolowos W, Voll RE,Manger B,GaiplU, et al. 2002. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 46:191-201
126. Rahman ZS, Shao WH, Khan TN, Zhen Y, Cohen PL. 2010. Impaired apoptotic cell clearance in the germinal center by Mer-deficient tingible body macrophages leads to enhanced antibody-forming cell and germinal center responses. J. Immunol. 185:5859-68
127. Khan TN, Wong EB, Soni C, Rahman ZS. 2013. Prolonged apoptotic cell accumulation in germinal centers ofMer-deficient mice causes elevated B cell and CD4+ Th cell responses leading to autoantibody production. J. Immunol. 190:1433-46
128. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, et al. 2006. Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9:173-87
129. Meesters EW, Hansen H, Spronk HM, Hamulyak K, Rosing J, et al. 2007. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul. Fibrinolysis 18:21-28
130. Suh CH, Hilliard BA, Li S, Merrill JT, Cohen PL. 2010. TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res. Ther. 12:R146
131. Song KS, Park YS, Kim HK. 2000. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 43:557-60
132. Cooper DN, Ball EV, Stenson PD, Phillips AD, Howells K, et al. 2013. The Human Gene Mutation Database. Inst. Med. Genet. , Cardiff, updated June 2013. http://www. hgmd. cf. ac. uk/ac/index. php
133. Duebgen S, Kauke T, Marschall C, Giebl A, Lison S, et al. 2012. Genotype and laboratory and clinical phenotypes of protein s deficiency. Am. J. Clin. Pathol. 137:178-84
134. Alhenc-Gelas M, Canonico M, Morange PE, Emmerich J, Geht Genetic Thrombophilia Group. 2010. Protein S inherited qualitative deficiency: novel mutations and phenotypic influence. J. Thromb. Haemost. 8:2718-26
135. Caspers M, Pavlova A, Driesen J, Harbrecht U, Klamroth R, et al. 2012. Deficiencies of antithrombin, protein C and protein S-practical experience in genetic analysis of a large patient cohort. Thromb. Haemost. 108:247-57
136. Shindo A, Ikejiri M, Ii Y, Nakatani K, Wada H, et al. 2012. A novel protein S gene mutation combined with protein S Tokushima mutation in a patient with superior sagittal sinus thrombosis. J. Neurol. 259:178-79
137. Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, et al. 2010. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica 95:1563-71
138. Zhu T, Ding Q, Bai X, Wang X, Kaguelidou F, et al. 2011. Normal ranges and genetic variants of antithrombin, proteinCand protein S in the generalChinese population. Results of the ChineseHemostasis Investigation on Natural Anticoagulants Study I Group. Haematologica 96:1033-40
139. Leung TW, Yip SF, Lam CW, Chan TL, Lam WW, et al. 2010. Genetic predisposition of white matter infarction with protein S deficiency and R355C mutation. Neurology 75:2185-89
140. Kasperaviciute D, Catarino CB,Chinthapalli K, Clayton LM, Thom M, et al. 2011. Uncovering genomic causes of co-morbidity in epilepsy: gene-driven phenotypic characterization of raremicrodeletions. PLOS ONE 6:e23182
141. Lind-Hallden C, Dahlen A, Hillarp A, Zoller B, Dahlback B, Hallden C. 2012. Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency. Thromb. Haemost. 108:94-100
142. Bruno DL, Stark Z, Amor DJ, Burgess T, Butler K, et al. 2011. Extending the scope of diagnostic chromosome analysis: detection of single gene defects using high-resolution SNP microarrays. Hum. Mutat. 32:1500-6
143. Kim HJ, Kim DK, Yoo KY, You CW, Yoo JH, et al. 2012. Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array. Haematologica 97:304-9
144. Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N. 2007. Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. Hepatogastroenterology 54:1417-21
145. Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, et al. 2010. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagul. Fibrinolysis 21:118-21
146. Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, et al. 2000. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 95:190-94
147. Koutroumpakis EI, Tsiolakidou G, Koutroubakis IE. 2013. Risk of venous thromboembolism in patients with inflammatory bowel disease. Semin. Thromb. Hemost. 39:461-68
148. Engelmann B, Massberg S. 2013. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13:34-45
149. van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, et al. 2013. Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis. Arthritis Rheum. 65:671-80
150. Gonzalez NA, Bensinger SJ, Hong C, Beceiro S, Bradley MN, et al. 2009. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31:245-58
151. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, et al. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J. Immunol. 183:2167-75
152. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, et al. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80:10109-16
153. Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, et al. 2011. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9:286-98
154. Shimojima M, Stroher U, Ebihara H, Feldmann H, Kawaoka Y. 2012. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J. Virol. 86:2067-78
155. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, et al. 2012. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12:544-57
156. Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, et al. 2011. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology 415:83-94
157. Mercer J, Helenius A. 2010. Apoptotic mimicry: phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann. NY Acad. Sci. 1209:49-55
158. Shimojima M, Ikeda Y, Kawaoka Y. 2007. The mechanism of Axl-mediated Ebola virus infection. J. Infect. Dis. 196(Suppl. 2):S259-63
159. DraymanN,Glick Y, Ben-nun-shaulO, Zer H, Zlotnick A, et al. 2013. Pathogens use structuralmimicry of native host ligands as a mechanism for host receptor engagement. Cell Host Microbe 14:63-73
160. Subramanian M, HayesCD,ThomeJJ, ThorpE,MatsushimaGK, et al. 2014. An AXL/LRP-1/RANBP9 complexmediatesDCefferocytosis and antigen cross-presentation in vivo. J. Clin. Investig. 124:1296-308
161. Joffre OP, Segura E, Savina A, Amigorena S. 2012. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12:557-69
162. Shibata T, Habiel DM, Coelho AL, Kunkel SL, Lukacs NW, Hogaboam CM. 2014. Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma. J. Immunol. 192:3569-81
163. Sullivan BM, Welch MJ, Lemke G, Oldstone MB. 2013. Is the TAM receptor Axl a receptor for lymphocytic choriomeningitis virus? J. Virol. 87:4071-74
164. Taylor IC, Roy S, Yaswen P, Stampfer MR, VarmusHE. 1995. Mousemammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. J. Biol. Chem. 270:6872-80
165. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. 1995. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene 10:2349-59
166. KeatingAK, SalzbergDB, Sather S, LiangX,Nickoloff S, et al. 2006. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 25:6092-100
167. Linger RM, Keating AK, Earp HS, Graham DK. 2010. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin. Ther. Targets 14:1073-90
168. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, et al. 2010. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 115:2264-73
169. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, et al. 2013. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122:2443-52
170. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, et al. 2010. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12:116-27
171. Cook RS, Jacobsen KM,Wofford AM,DeRyckere D, Stanford J, et al. 2013. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J. Clin. Investig. 123:3231-42
172. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, et al. 2014. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507:508-12
173. Caraux A, Lu Q, Fernandez N, Riou S, Di Santo JP, et al. 2006. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat. Immunol. 7:747-54
174. Akitake-Kawano R, Seno H, Nakatsuji M, Kimura Y, Nakanishi Y, et al. 2013. Inhibitory role of Gas6 in intestinal tumorigenesis. Carcinogenesis 34:1567-74
175. Hong C, Kidani Y, A-Gonzalez N, Phung T, Ito A, et al. 2012. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J. Clin. Investig. 122:337-47
176. Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL, Cohen PL. 2003. The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity. Eur. J. Immunol. 33:2160-67
177. WalletMA, Sen P, Flores RR, Wang Y, Yi Z, et al. 2008. MerTK is required for apoptotic cell-induced T cell tolerance. J. Exp. Med. 205:219-32
178. Bosurgi L, Brunelli S, Rigamonti E,Monno A, Manfredi AA, Rovere-Querini P. 2015. Vessel-associated myogenic precursors control macrophage activation and clearance of apoptotic cells. Clin. Exp. Immunol. 179:62-67
179. Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, et al. 2009. PPAR-δsenses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 15:1266-72
180. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, et al. 2009. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31:245-58
181. GouldWR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, et al. 2005. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J. Thromb. Haemost. 3:733-41
182. Chen C, Li Q, Darrow AL, Wang Y, Derian CK, et al. 2004. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler. Thromb. Vasc. Biol. 24:1118-23
183. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, et al. 2014. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40:91-104
184. Jennings JH, Linderman DJ, Hu B, Sonstein J, Curtis JL. 2005. Monocytes recruited to the lungs of mice during immune inflammation ingest apoptotic cells poorly. Am. J. Respir. Cell Mol. Biol. 32:108-17
185. Deng T, Zhang Y, Chen Q, Yan K, Han D. 2012. Toll-like receptor-mediated inhibition of Gas6 and ProS expression facilitates inflammatory cytokine production in mouse macrophages. Immunology 135:40-50
186. Todt JC, Hu B, Curtis JL. 2004. The receptor tyrosine kinase MerTK activates phospholipase Cγ2 during recognition of apoptotic thymocytes by murine macrophages. J. Leukoc. Biol. 75:705-13
187. ShaoWH, Zhen Y, Eisenberg RA, Cohen PL. 2009. The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clin. Immunol. 133:138-44
188. Shao WH, Eisenberg RA, Cohen PL. 2008. The Mer receptor tyrosine kinase is required for the loss of B cell tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J. Immunol. 180:7728-35
189. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, et al. 2014. The cellular and molecular origin of tumor-associated macrophages. Science 344:921-25
190. Hilliard BA, Zizzo G, Ulas M, Linan MK, Schreiter J, Cohen PL. 2014. Increased expression of Mer tyrosine kinase in circulating dendritic cells and monocytes of lupus patients: correlations with plasma interferon activity and steroid therapy. Arthritis Res. Ther. 16:R76
191. Hodrea J, MajaiG,DoroZ,ZahuczkyG, Pap A, et al. 2012. The glucocorticoid dexamethasone programs human dendritic cells for enhanced phagocytosis of apoptotic neutrophils and inflammatory response. J. Leukoc. Biol. 91:127-36
192. Zahuczky G, Kristof E, Majai G, Fesus L. 2011. Differentiation and glucocorticoid regulated apoptophagocytic gene expression patterns in human macrophages. Role of Mertk in enhanced phagocytosis. PLOS ONE 6:e21349
193. Uehara H, Shacter E. 2008. Auto-oxidation and oligomerization of protein s on the apoptotic cell surface is required for mer tyrosine kinase-mediated phagocytosis of apoptotic cells. J. Immunol. 180:2522-30
194. Heide I, Sokoll AC, Henz BM, Nagel S, Kreissig K, et al. 1998. Regulation and possible function of axl expression in immature human mast cells. Ann. Hematol. 77:199-205
195. Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. 2009. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood 113:2470-77
196. Park IK, Trotta R, Yu J, Caligiuri MA. 2013. Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. Eur. J. Immunol. 43:2750-55
197. Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG. 2008. Overexpression of apoptotic cell removal receptor MERTK in alveolar macrophages of cigarette smokers. Am. J. Respir. Cell Mol. Biol. 39:747-57
198. ZagorskaA,Traves PG,Lew ED,Dransfield I, LemkeG. 2014. Diversification ofTAMreceptor tyrosine kinase function. Nat. Immunol. 15:920-28
199. Lew ED, Oh J, Burrola PG, Lax I, Zagorska A, et al. 2014. Differential TAM receptorligand-phospholipid interactions delimit differential TAM bioactivities. eLife 3:e03385. doi: 10. 7554/eLife. 03385
200. Tsou WI, Nguyen KQ, Calarese DA, Garforth SJ, Antes AL, et al. 2014. Receptor tyrosine kinases, TYRO3, AXL, andMER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J. Biol. Chem. 289:25750-63
201. Graham DK, DeRyckere D, Davies KD, Earp HS. 2014. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14:769-85